Biotech Stocks Blog

EDAP TMS, Back on the Map (EDAP)

admin — Wed, 10 Mar 2010 02:12:13 +0000

Submitted by BioHealth Investor Blog EDAP TMS SA (NASDAQ: EDAP) is a French company which makes medical devices for the treatment of urological diseases and the company’s stock is soaring after the company was granted marketing approval of its newly designed, high-end Sonolith I-Sys lithotripsy device by the Japanese Administration. Because this market is still under-served, [...]

EDAP TMS, Back on the Map (EDAP)

admin — Wed, 10 Mar 2010 02:11:16 +0000

Submitted by BioHealth Investor Blog Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) has a big event on deck this week. This Friday, March 12, is its Prescription Drug User Fee Act (PDUFA) action date for an FDA panel to issue a recommendation on Byetta as the the first once a week treatment for Type II diabetes. The date [...]

Amylin & Friends Brace for Diabetes Review (AMLN, LLY, ALKS)

admin — Wed, 10 Mar 2010 02:08:50 +0000

The Changing Landscape of Biotech Valuations (ACOR, CBST, MNKD, INCY, SGEN, ITMN, IPXL, MRX, SVNT, VPHM)

admin — Wed, 10 Mar 2010 02:07:55 +0000

Submitted by BioHealth Investor Blog The biotech and biohealth universe is changing in size. In 2008 and 2009, partly due to mergers and partly due to market valuations, there had become a surprisingly small number of biotech stocks which had market capitalization rates of more than $1 billion. At one point there were only about 10 [...]

When Biotech Layoffs Come (XNPT)

admin — Sat, 06 Mar 2010 00:50:43 +0000

Submitted by BioHealth Investor Blog When conglomerates and consumer products lay off workers and employees, shareholders generally cheer the company for saving money and cutting costs by figuring out productivity measures that milk more output per employee. That leaves more income and ultimately brings more dividends down the road. But biotech firms are far from being [...]

Winning from Boosting Good Cholesterol (RVXCF, RVX, PFE, AZN, MRK)

admin — Sat, 06 Mar 2010 00:49:34 +0000

Submitted by BioHealth Investor Blog BioHealthInvestor usually sticks to US companies or at least sticks to ADRs for investors. But sometimes there is a much larger bit of data either north of the border or in Europe. There is a company called Resverlogix Corp. which trades in Canada under the ticker ‘RVX’ and the stock also [...]

Talking Biotech ETFs: iShares Nasdaq Biochnology to $100 (IBB, OSIP, MDVN)

admin — Sat, 06 Mar 2010 00:48:35 +0000

Submitted by BioHealth Investor Blog Today’s price moves in the biotech sector are quite different from what we saw earlier this week. A hostile merger via tender from Astellas for OSI Pharmaceuticals Inc. (NASDAQ: OSIP) got everyone up in arms this week. So much that other investors were going back over buyout candidate notes. We also [...]

Biotech Implosion: Medivation, Alzheimer’s Beats Drug (MDVN, PFE)

admin — Sat, 06 Mar 2010 00:47:37 +0000

Submitted by BioHealth Investor Blog Medivation, Inc. (NASDAQ: MDVN) is the next biotech implosion. The company’s highly awaited Phase III study on its Alzheimer drug called Dimebon did not meet expectations. It failed to meet primary and secondary endpoints. The problem is that this was hitting 52-week highs yesterday. The company did note that a separate Phase [...]

More Biotech Buyout or M&A Targets (OSIP, VRTX, AUXL, ITMN, HGSI, CELG, DNDN, ENZN, FACT, PBE, XBI)

admin — Wed, 03 Mar 2010 02:12:37 +0000

Submitted by BioHealth Investor Blog After today’s hostile Astellas offer for OSI Pharmaceuticals (NASDAQ: OSIP), we have investors and traders alike looking for ‘the next takeover target’ in biotech. Buy now you know that there are many pitfalls in simply looking for biotech stocks to buy because they will be taken over. We have taken a [...]

Hostile Mergers Back in Biotech (OSIP)

admin — Wed, 03 Mar 2010 02:07:01 +0000

Submitted by BioHealth Investor Blog Mergers are back in biotech…. Astellas Pharma Inc., a global pharmaceutical company in Japan, announced that it will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals (NASDAQ: OSIP). The direct tender is nothing short of a hostile merger after Astellas said that OSI has [...]

Generic Drug Wars… Is Dr. Reddy’s The Answer? (RDY, TEVA, GSK)

admin — Mon, 01 Mar 2010 01:22:42 +0000

Submitted by BioHealth Investor Blog Generic drugs are just one of the many combined issues that are coming front and center in the world of healthcare reform. Frankly this is not a new notion. Not all. This weekend came a feature in Barron’s “Asian Trader: Pill Maker That’s Set To Pop” calling Dr. Reddy’s Laboratories Ltd. [...]

Making sure pills go down, and money flows

admin — Sat, 27 Feb 2010 21:24:39 +0000

Submitted by PharmaGossip When drugs maker Wyeth Australia wanted its arthritis drug Enbrel listed on the pharmaceutical benefits scheme (PBS) it hired political lobby group Parker & Partners to wheel out sick kids in its meetings with politicians. The image of arthritic 10-year-olds, together with the threat of a bleeding heart media campaign, was so potent that [...]

Sackler Brothers Ties to Purdue Pharma and Profits

admin — Sat, 27 Feb 2010 21:23:34 +0000

Submitted by PharmaGossip via salem-news.com Pic - Richard Sackler, co-chairman of Stamford, Connecticut based Purdue Pharma and adjunct professor of genetics at Rockefeller University. Visit 1800blogger to see all of our industry leading blogs.

Drug ad claims - Ben Goldacre takes a sniff

admin — Sat, 27 Feb 2010 21:21:58 +0000

Submitted by PharmaGossip How closely do the great and the good, for example, scrutinise the promotional material for medical drugs? The latest paper looking at this question is published this month. Researchers in Holland went through the world’s biggest medical journals – the Journal of the American Medical Association, Lancet, the New England Journal of Medicine, and [...]

PharmedOut Conference: June 25th 2010

admin — Sat, 27 Feb 2010 16:25:01 +0000

Submitted by PharmaGossip PharmedOut is pleased to announce a conference. “Prescription for Conflict: Should Industry Fund Continuing Medical Education?” will be held on Friday, June 25, 2010, on the Georgetown campus in Washington DC. We intend to address the questions: Does drug industry funding of CME adversely affect the educational content of CME? If so, can commercial [...]

Pfizer - Rapamune: DOJ conducts criminal probe

admin — Sat, 27 Feb 2010 03:27:01 +0000

Submitted by PharmaGossip Federal prosecutors in Oklahoma are conducting a criminal investigation of a Pfizer unit’s promotional practices for organ-transplant drug Rapamune, the drug maker disclosed Friday. New York-based Pfizer said in a regulatory filing the U.S. Attorney’s office for the western district of Oklahoma was conducting the probe. There were no further details in the regulatory [...]

Judge Declines to Upset $22.5 Million Jury Award in Polio Case

admin — Fri, 26 Feb 2010 22:28:39 +0000

Submitted by PharmaGossip A New York state judge has refused to throw out the $22.5 million verdict awarded by a Staten Island jury in a 28-year-old polio vaccine suit. Last year, the jury found Pfizer Inc., as successor to Lederle Laboratories, liable for negligent manufacture of the oral polio vaccine from which plaintiff Dominick Tenuto allegedly [...]

Celebrating US Whistleblowers

admin — Thu, 25 Feb 2010 21:54:52 +0000

Submitted by PharmaGossip Visit 1800blogger to see all of our industry leading blogs.

GSK - Avandia: Harlan Krumholz MD writes in Forbes

admin — Thu, 25 Feb 2010 21:32:35 +0000

Submitted by PharmaGossip I want to believe in America’s pharmaceutical companies. I want to believe that people in these companies believe that the best strategy for success is to do what is best for patients. I want to believe that they are interested in scientific truth and eager to know of any safety issues and ready [...]

Cost of Cancer

admin — Wed, 24 Feb 2010 21:18:22 +0000

Submitted by Health Economics Dear All, please find below link of an interesting piece of work on the cost of cancer in the UK. best Ulf http://www.policyexchange.org.uk/images/publications/pdfs/The_Cost_of_Cancer_-_Feb__10.pdf Visit 1800blogger to see all of our industry leading blogs.

InterMune Volatility Compression (ITMN)

admin — Tue, 23 Feb 2010 04:33:48 +0000

Submitted by BioHealth Investor Blog InterMune Inc. (NASDAQ: ITMN) has shown some very interesting options trading, and the trading looks to be a bet against all that huge volatility we have seen. Joe Kunkle of OptionsHawk.com noted: ITMN with a 2,000X4,000X2,000 contract butterfly call spreads at the March $25/$30/$35 strikes. This trade bets on volatility to collapse, which [...]

Two key Analyst Call in BioHealth Space (DNDN, HGSI)

admin — Tue, 23 Feb 2010 04:32:07 +0000

Submitted by BioHealth Investor Blog We have seen two very key biotech analyst calls this morning, and shares of both are responding. Dendreon Corp. (NASDAQ: DNDN) and Human Genome Sciences (NASDAQ: HGSI) were both given positive brokerage initiations this morning. Dendreon Corp. (NASDAQ: DNDN) is seeing gains this morning after the stock was started as “Overweight” and [...]

Buyout Rumors Resurface in Biotech, Maybe (DNDN, MYGN)

admin — Mon, 22 Feb 2010 03:56:16 +0000

Submitted by BioHealth Investor Blog Sometimes it is the action seen in stock options gets traders moving more than the action in the stock. With more commentators on CNBC and other media outlets talking about ‘elevated options trading seen in…’ it gets even more on alert. From our best read today, that seems to be the [...]

THE HEALTH ECONOMICS BLOG - Trends, Politics, Opinions etc. in biotech & pharma industry

admin — Fri, 19 Feb 2010 01:26:28 +0000

Submitted by THE HEALTH ECONOMICS BLOG … am sure that will be very welcomed news by the consultants among the readers Cheers Ulf Pharmacoeconomics to Get Bigger Budgets, According to Preliminary Survey Results Marketwire News Releases Published: 02/15/10 12:12 PM EST Cutting Edge Information Reports Findings From Ongoing Study RESEARCH TRIANGLE PARK, NC — (Marketwire) — 02/15/10 — This year, drug makers’ [...]

Rigel Attacks Rheumatoid Arthritis with AstraZeneca (RIGL, AZN)

admin — Fri, 19 Feb 2010 01:25:11 +0000

Submitted by BioHealth Investor Blog Rigel Pharmaceuticals (NASDAQ: RIGL) may be the biotech winner this Tuesday. The company has signed a pact with AstraZeneca (NYSE: AZN) which could ultimately bring in about $1.25 billion if all targets are met. This pact is a licensing agreement for Rigel’s rheumatoid arthritis drug R788 or fostamatinib disodium. Rigel said last [...]